Core Viewpoint - WuXi AppTec (02268.HK) has announced a placement agreement with Morgan Stanley to issue up to 22.277 million shares at a price of HKD 58.85 per share, representing a discount of approximately 4.00% from the last closing price of HKD 61.30 [1] Group 1: Placement Details - The maximum number of shares to be placed represents approximately 1.85% of the existing issued share capital and about 1.82% of the enlarged issued share capital after the placement [1] - The total expected proceeds from the placement will be approximately HKD 1.311 billion (around USD 168 million), with net proceeds estimated at about HKD 1.301 billion (around USD 167 million) [1] Group 2: Use of Proceeds - Approximately 90% of the net proceeds will be used to further expand the group's service capabilities and production capacity, including clinical and commercial production capacity for bioconjugates, active pharmaceutical ingredients, and products [1] - About 10% of the net proceeds will be allocated for the group's working capital needs and general corporate purposes [1]
药明合联(02268.HK)拟折价配股募资13亿港元 加速生物偶联药物等产能布局